Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) is projected to announce its earnings results before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($1.23) per share for the quarter.
Phio Pharmaceuticals Stock Down 1.5 %
Shares of PHIO stock opened at $1.29 on Monday. The company has a 50 day moving average price of $1.71 and a 200-day moving average price of $2.41. Phio Pharmaceuticals has a 52 week low of $1.22 and a 52 week high of $9.79. The firm has a market capitalization of $8.89 million, a PE ratio of -0.12 and a beta of 1.28.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright restated a “buy” rating and issued a $4.00 price objective on shares of Phio Pharmaceuticals in a research note on Wednesday, February 19th.
Phio Pharmaceuticals Company Profile
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.
Read More
- Five stocks we like better than Phio Pharmaceuticals
- How Can Investors Benefit From After-Hours Trading
- Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners
- 3 Fintech Stocks With Good 2021 Prospects
- MarketBeat Week in Review – 03/24 – 03/28
- How to Short a Stock in 5 Easy Steps
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
